Client’s Testimonial:
“I had an excellent experience working with Chen Immigration Law Associates (WeGreened) on my employment-based immigration petitions. From start to finish, the team was highly professional, knowledgeable, detail-oriented, and exceptionally well organized.
I am especially grateful to my attorneys and the entire team for their outstanding expertise, accurate judgment, and clear strategic guidance. Based on their advice, I pursued both NIW and EB1A petitions, which turned out to be an excellent decision. Thanks to their careful planning and strong case preparation, my I-140 was approved in a timely manner, allowing me to confidently move forward with my H-1B renewal planning.
Throughout the process, the team responded promptly to my questions, explained each step clearly, and paid close attention to every detail of my case. Their professionalism and transparency gave me great confidence during an otherwise complex and stressful process.
I truly appreciate their dedication and high standards of work. I am happy to have my success story shared and sincerely hope it will help others considering employment-based immigration options. I would highly recommend Chen Immigration / WeGreened to anyone pursuing EB-1, NIW, or other employment-based immigration petitions.”
On January 14th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Research Associate in the field of Pharmacology (Approval Notice).
General Field: Pharmacology
Position at the Time of Case Filing: Senior Research Associate
Country of Origin: China
State of Residence at the Time of Filing: Texas
Approval Notice Date: January 14th, 2026
Processing Time: 9 months, 26 days (Premium Processing Requested)
Case Summary:
One independent expert summarized the value of this work in plain terms: “[Client] supports innovation in oncology and drives progress in related areas of cancer biology and drug development by advancing pharmacological research in the United States.”
Targeted cancer therapy often succeeds or fails on a practical tradeoff. The drug must be potent enough to eliminate tumor cells, but precise enough to avoid collateral damage to healthy tissue. This NIW case centered on a pharmacology researcher whose work addresses that tradeoff directly by improving drug-conjugate therapies. The scientific goal is straightforward: make the “delivery vehicle” more selective, so the therapeutic payload reaches tumor cells more reliably and causes fewer off-target effects.
North America Immigration Law Group (NAILG) structured the case around two adjudicator-friendly themes: (1) why this research direction matters at a systems level for cancer care, and (2) why the record showed the client can keep pushing it forward in the United States. The filing emphasized that these targeted drug-conjugate strategies reflect a more modern treatment logic, engineering therapeutic delivery to concentrate in tumor cells while limiting exposure to healthy tissue, improving both effectiveness and tolerability in settings where current options remain limited or overly toxic.
A distinguishing feature of this record was external validation that the work aligns with national health priorities. The case highlighted competitive support from the National Institutes of Health (NIH) and the Cancer Prevention and Research Institute of Texas (CPRIT), reinforcing that the underlying research direction has been evaluated and backed by major decision-makers funding cancer-focused innovation.
The “well-positioned” showing was built on execution. The client holds a Ph.D. in Pharmacology and has an established record of research output and influence: 25 peer-reviewed journal articles (6 of them first-authored), 1 abstract, 2 preprints, and 977 citations. Importantly, those citations were presented as evidence of independent reliance, showing that other scientists have used the client’s findings to inform ongoing work across multiple disease and safety contexts, including treatment strategy development in oncology and refinement of therapeutic approaches where efficacy must be balanced with risk.
USCIS approved the NIW petition, recognizing a record that linked sophisticated pharmacology to a clear public-health need: safer, more specific cancer therapies that improve outcomes while reducing harmful side effects. NAILG appreciated the opportunity to present this work in a clear, privacy-conscious way and to secure a result that supports continued progress in targeted oncology drug development in the United States.
North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).
Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend
With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.
We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours
With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.
Vast Majority of Clients Came to Us Because of Referrals
For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.
Track Record of Success EB-1 and NIW Approvals
Approval Notices: https://www.wegreened.com/eb1_niw_approvals
Success Stories: https://www.wegreened.com/blog/
Website: www.wegreened.com
Free evaluation: https://www.wegreened.com/Free-Evaluation
Tel: 888.666.0969 (Toll Free)
To see more clients’ testimonials and approvals, please refer to:
To Learn More About Your Options CLICK HERE
Copyright © North America Immigration Law Group – WeGreened.com, All Rights Reserved.